AI app to monitor and support nutrition after pancreatic cancer surgery

Evaluation of a Combined PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.

This will test whether an AI app that collects symptoms, photos, and patient-reported data can help detect nutritional risk and guide support for people after radical pancreatic cancer surgery.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 200 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (Academic / other)
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT07167264 on ClinicalTrials.gov

What this trial studies

This is a prospective, randomized controlled exploratory trial enrolling 200 adults who have recovered from radical pancreatic cancer surgery. Participants are stratified by age, gender, TNM stage, ECOG score, and baseline BMI and randomized to an intervention arm using a PGHD‑AI app plus routine offline follow-up or to routine outpatient follow-up alone. The app collects patient-reported outcomes (strength, pain, bowel function, appetite, weight), corpus collection cards, and facial photographs to derive PGHD phenotypes, which are used to train AI agents to predict nutritional risk and propose interventions. The study follows participants for one year to compare prediction accuracy, intervention responses, and feasibility of AI‑guided nutritional management.

Who should consider this trial

Good fit: Adults 18–80 who have fully recovered from radical pancreatic cancer resection, have ECOG 0–1, can use an app and attend follow-up visits, and who consent to participate.

Not a fit: Patients with metastatic or recurrent disease, severe organ dysfunction, pregnancy or breastfeeding, a history of other recent cancers, or those unable or unwilling to use the app are unlikely to benefit.

Why it matters

Potential benefit: If successful, the tool could enable earlier, personalized nutritional support and more efficient follow-up to improve recovery and quality of life after pancreatic cancer surgery.

How similar studies have performed: Digital health and AI approaches using patient-reported data have shown early promise in monitoring nutrition or recovery in other cancer settings, but applying PGHD‑AI for post‑pancreatectomy nutritional management is largely novel and unproven.

Eligibility criteria

Inclusion Criteria:

1. Age: 18-80 years old, and voluntarily signed the informed consent form to participate in the study;
2. Meet the clinical and pathological diagnostic criteria for pancreatic cancer (ICD-10:C25);
3. After radical surgery, fully recovered from surgery at randomization;
4. ECOG PS score 0-1 ;
5. Have objective conditions to complete follow-up and examination during the study process.

Exclusion Criteria:

1. Patients or their families are willing to use the APP;
2. Current history or past history of metastatic or locally recurrent pancreatic cancer;
3. Combined with other serious organ dysfunctions (such as severe liver and kidney insufficiency, heart failure, etc.);
4. Women who are currently pregnant or lactating;
5. History of other tumor diseases in the past;
6. Other conditions that the study deems unsuitable for participation in the study, including but not limited to: patients with serious or uncontrollable medical conditions, safety risks, interference with the interpretation of study results, and impact on study compliance.

Where this trial is running

Shanghai, Shanghai Municipality

• Shanghai General Hospital — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Study coordinator: Long Jiang, MD

Conditions Pancreatic Cancer